NCT05113810 is a Phase 2 clinical trial of HCQ01 in 2019 Novel Coronavirus, sponsored by Ministry of Health Jordan.

Who is sponsoring NCT05113810?

NCT05113810 is sponsored by Ministry of Health Jordan.

What drugs are being tested in NCT05113810?

Interventions in NCT05113810: HCQ01, standard of care (SOC) for COVID-19.

What condition does NCT05113810 study?

NCT05113810 studies 2019 Novel Coronavirus.

Is NCT05113810 still recruiting?

NCT05113810 is currently status unknown. Last updated 7 March 2022.

Last reviewed 2022-03-07 · How we verify

NCT05113810

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19

Status unknown Phase 2 Last updated 7 March 2022

What this trial tests

Phase 2 trial testing HCQ01 in 2019 Novel Coronavirus in 110 participants. Status unknown.

Timeline

20 March 2022

Primary endpoint
20 July 2022

20 July 2022

Quick facts

Lead sponsor	Ministry of Health Jordan
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	110
Start date	20 March 2022
Primary completion	20 July 2022
Estimated completion	20 July 2022
Sites	1 location across Jordan

Drugs / interventions tested

HCQ01 — full drug profile →
standard of care (SOC) for COVID-19 — full drug profile →

Conditions studied

2019 Novel Coronavirus — all drugs for 2019 Novel Coronavirus →

Sponsor

Ministry of Health Jordan

Who can join

18 and older, any sex, with 2019 Novel Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized COVID-19 patients. The Jordanian Ministry of Health (MOH) is the study sponsor, and the study will be conducted at MOH COVID-19 hospitals. Approximately 110 patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 1:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow the MOH SOC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05113810 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Health Jordan
Last refreshed: 7 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05113810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing